KR101551293B1 - Composotion containing Convallaria keiskei extract for preventing or treating cancer - Google Patents

Abstract

The present invention relates to a composition for preventing or treating cancer, which comprises an extract of Liliaceae. The bark extract of the present invention has an excellent effect of inhibiting proliferation of cancer cells and inducing apoptosis of cancer cells, and thus can be usefully used for prevention or treatment of cancer.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for preventing or treating cancers,

The present invention relates to a composition for preventing or treating cancer comprising an extract of Liliaceae bark as an active ingredient.

Cancer is one of the growing diseases with the development of civilization, and there are surgical treatment, radiation therapy, and chemotherapy by the administration of anticancer drugs. However, these treatments are mostly limited to the treatment of early cancer patients or specific cancers, and the cancer deaths are steadily increasing. In particular, radiation therapy and chemotherapy have many problems such as causing many side effects. Therefore, development of an anticancer agent that can increase the rate of amalgamation while minimizing side effects is required. For this reason, attempts to develop anticancer agents from natural products, especially herbal medicines, have been continuously carried out. Although research on anticancer drugs has clearly developed, anticancer substances currently in use have problems such as failure of treatment due to various causes, anticancer drug resistance, and side effects. Therefore, it is necessary to focus on prevention rather than treatment using natural products, which are expected to have less side effects than synthesized chemicals.

Oral cancer can occur in the lips, tongue, inner surface of the cheek, palate, gums, and most of the oral cancer is squamous cell carcinoma, which occurs when the growth of oral surface cells is not properly controlled. In addition to surgery, radiotherapy or combination therapies have been developed for cancer treatment. However, oral cancer has a poor prognosis than other cancers. The reason for the poor prognosis and high mortality rate of oral cancer compared to other cancers is that the prognosis is poor due to the advanced cancer spreading to the surrounding tissues at diagnosis and recurrence or secondary primary cancer after curative surgery, , Compared to other cancers in the ENT area (laryngeal cancer and maxillary sinus cancer). However, due to these characteristics of oral cancer, administration of chemopreventine agents or chemopreventine agents that can inhibit cancer after combination therapy such as radical surgery, radiation therapy, and chemotherapy for oral cancer plays an important role in increasing the survival rate of oral cancer patients . Therefore, it is urgent to develop an effective and stable cancer prevention agent in the treatment of oral cancer.

On the other hand, Lily of the valley is a perennial herb that is distributed in mountains around the country. It has subterranean stems and many fine roots that grow sideways. Two to three broad elliptical leaves grow from the roots. ~ 8 flowers bloom in the same direction at regular intervals. The shape of the flower is like a drop and it is said to be a lily of the valley because its color is white. The diameter of the flower is about 5 mm and the end is divided into six branches.

The lily of the valley is also called Youngran, Chofaran, and Chogokyeong, and all parts including root are used as medicines. Lily of the valley also contains alkaloids such as Convallamarin, Convallatoxin, Convallarin and Xanthophyll, and is one of the toxic plants. Hypertension, diarrhea, and has the effect of helping blood circulation, and is used for the treatment of heart weakness, edema, symptoms that do not easily urinate, bruises, and sprains.

The inventors of the present invention have confirmed that the extract of Liliaceae has an excellent anticancer effect while studying natural products and compounds separated therefrom in order to develop a drug having an excellent effect of preventing or treating cancer and completed the present invention.

It is an object of the present invention to provide a composition for preventing or treating cancer comprising an extract of Liliaceae bark as an active ingredient.

In order to accomplish the above object, the present invention provides a pharmaceutical composition for preventing or treating cancer comprising an extract of Liliaceae bark as an active ingredient.

The present invention also provides a food composition for preventing or ameliorating cancer comprising an extract of Liliaceae bark as an active ingredient.

The bark extract of the present invention has an excellent effect of inhibiting proliferation of cancer cells and inducing apoptosis of cancer cells, and thus can be usefully used for prevention or treatment of cancer.

1 is a graph showing cell survival rate of MC3 cells according to treatment concentration of Lily of the Valley.
2 is a graph showing the cell survival rate of HN22 cells according to the treatment concentration of Lily of the Valley.
FIG. 3 is a graph showing the degree of damage to cell nuclei due to DNA fragmentation in MC3 cells treated with L. radix extract. FIG.
FIG. 4 is a graph showing the degree of damage to the cell nucleus due to DNA fragmentation in HN22 cells treated with L. radix extract.
FIG. 5 is a graph showing the expression level of cleaved-caspase-3 in MC3 cells treated with L. radix extract.
FIG. 6 is a graph showing the degree of cleaved-PARP expression in MC3 cells treated with L. radix extract.
FIG. 7 is a graph showing the expression level of Mcl-1 protein in MC3 cells treated with L. radix extract.
8 is a graph showing the concentration of cytochrome c in the cell matrix in MC3 cells treated with L. radix extract.
9 is a graph showing the degree of phosphorylation of eIF4E and 4EBP1 in MC3 cells treated with L. radix extract.

The present invention provides a composition for preventing or treating cancer comprising an extract of Liliaceae bark as an active ingredient.

The composition comprises a pharmaceutical composition and a food composition.

Hereinafter, the present invention will be described in detail.

The extract of Liliaceae which is an active ingredient of the present invention can be obtained by extracting by a conventional method, and commercially available ones can be purchased and used. Typical extraction methods include, but are not limited to, ultrasonic extraction, filtration, and reflux extraction.

In the present invention, the extract of Liliaceae can be obtained by the following method.

First, the lily of the valley is dried and finely cut, and then extracted into an extraction solvent by any method such as cold-watering, percolation, warming, etc. to obtain an extract containing the active ingredient. The extraction solvent is not limited thereto, but one or more solvents selected from water, C ₁ to C ₄ alcohols or mixed solvents thereof may be used, and methanol is preferably used. After filtration of the Liliaceae extract, the solvent is evaporated and concentrated to give the final Liliaceae extract.

The extract of Liliaceae according to the present invention has an excellent effect of inducing apoptosis of cancer cells and suppressing cell proliferation of cancer cells, and thus can be effectively used for prevention or treatment of cancer.

The cancer may be selected from the group consisting of oral cancer, liver cancer, stomach cancer, colon cancer, breast cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, skin cancer, cervical cancer, ovarian cancer, colon cancer, small bowel cancer, Cancer of the prostate, cancer of the prostate, cancer of the endometrium, cancer of the endometrium, cancer of the thyroid, pituitary cancer, soft tissue sarcoma, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, But are not limited to, acute leukemia, lymphocytic lymphoma, renal or urothelial cancer, renal cell carcinoma, renal pelvic carcinoma, central nervous system tumor, primary central nervous system lymphoma, spinal cord tumor, brainstem glioma and pituitary adenoma.

The oral cancer may include sarcoma arising in oral squamous cell carcinoma, adenocystic carcinoma, mucinous epidermoid carcinoma, salivary gland cancer, jawbone or facial muscles, malignant melanoma of oral mucosa, and lymphoma occurring in oral cavity. It is not.

The composition of the present invention may contain one or more known active ingredients having the effect of preventing or treating cancer together with the extract of Liliaceae.

The compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions. In addition, it can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral formulations such as syrups and aerosols, external preparations, suppositories and sterilized injection solutions according to a conventional method. Suitable formulations known in the art are preferably those as disclosed in Remington ' s Pharmaceutical Science, recently, Mack Publishing Company, Easton PA. Examples of carriers, excipients and diluents which may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Examples of the liquid preparation for oral administration include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The term "administering" as used herein is intended to provide any individual of the invention with a composition of the invention in any suitable manner.

The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the individual, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. For the desired effects, the Liliaceae extract of the present invention may be administered in an amount of 1 mg / kg to 1000 mg / kg per day, and may be administered once a day or several times a day.

The pharmaceutical composition of the present invention may be administered to a subject in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.

The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the prevention and treatment of cancer.

In the present invention, the term "health functional food" refers to a food having a biological control function such as prevention and improvement of disease, bio-defense, immunity, recovery after disease and aging inhibition.

The composition of the present invention can be added to a health functional food for the purpose of preventing or improving cancer. When the Lilium berry extract of the present invention is used as a food additive, the Lilium berry extract may be directly added or used in combination with other food or food ingredients, and may be appropriately used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, in the production of foods or beverages, the Liliaceae extract of the present invention is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.

There is no particular limitation on the kind of the food. Examples of foods to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, natural sweeteners such as dextrin and cyclodextrin, synthetic sweeteners such as saccharine and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 10 g, preferably about 0.01 to 0.1 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, A carbonating agent used in a carbonated beverage, and the like. In addition, the composition of the present invention may comprise flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, preferred examples, experimental examples, and formulation examples are provided to facilitate understanding of the present invention. However, the following examples, experimental examples and preparation examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited thereto.

Example 1: Preparation of Lily of the Valley

Methanol extract of Convallaria keiskei (MECK) was purchased from Korea Plant Extract Bank, Korea Research Institute of Bioscience and Biotechnology, and used for the following experiments.

Experimental Example 1. Cytotoxicity of the Lily of the Valley of the Present Invention to Cancer Cells

The following experiment was conducted to confirm the cytotoxicity of the extract of Liliaceae of the present invention against cancer cells. In the following experiments, the methanol extract of Liliaceae obtained in Example 1 was dissolved in DMSO and used.

1-1. Preparation and Culture of Oral Cancer Cells

Human oral cancer cell line MC3 cells were received from China Fourth military medical university, and another human oral cancer cell line, HN22 cells, was received from Dankook University. The cells were treated with DMEM medium supplemented with 10% FBS and 100 U / MI penicillin / streptomycin, and then cultured under culture conditions of 5% CO ₂ and 37 ° C.

1-2. Effect of Lily of the Valley Plant Extract on the Cell Survival of Oral Cancer Cells

In order to confirm the cancer cell killing effect of the Liliaceae extract of the present invention, MC3 cells and HN22 cells, which are human oral cancer cell lines prepared as described in 1-1, were treated with the extract of Liliaceae, and then the cells were treated with a heamocytometer Cell viability was measured.

Specifically, MC3 cells and HN22 cells, which are human oral cancer cell lines, were divided into 6-well plates and cultured to a cell growth of about 50 to 60%. MC3 cells cultured in this manner were treated with 2, 4 and 8 ㎍ / ㎖ of L. bark extract and 5 and 10 ㎍ / ㎖ of L. bark extract on HN22 cells, respectively. Control group was treated with 0.1% DMSO. After each cell was cultured for 24 hours, the medium was removed and 0.04% trypan blue was added. By measuring the number of living cells using a heamocytometer, the cancer cell killing effect of the Lily of the Valley was confirmed. The results are shown in Fig. 1 and Fig.

As shown in FIG. 1 and FIG. 2, the human oral cancer cells treated with the extract of Liliaceae according to the present invention showed a decrease in cell survival rate depending on the concentration of Liliaceae extract.

Therefore, it can be seen that the extract of Lily of the Valley of the present invention induces apoptosis of oral cancer cells and thus exhibits excellent anticancer effect.

Experimental Example 2. Determination of inducing effect of apolipoprotein extract of the present invention on apoptosis

2-1. Identification of DNA fragmentation by Lily of the Valley

In order to confirm the apoptosis-inducing effect of the extract of Liliaceae of the present invention on oral cancer cells, it was observed whether DNA fragmentation occurred in oral cancer cells treated with the Liliaceae extract of the present invention.

Specifically, cells treated with the extract of Liliaceae bark extract as described above 1-2 were collected, centrifuged at 4,000 rpm at 4 ° C for 5 minutes to remove the supernatant, washed twice with PBS, and then washed with 100% For 10 minutes. The immobilized cells were centrifuged at 4,000 rpm for 5 minutes at 4 ° C to remove the immobilized solution, and the cells were resuspended in 200 μl of PBS. Then, 50 μl of the cell suspension was dropped on a slide glass, Of DAPI (4'-6-diamidino-2-phenylindole) solution was added and stained at room temperature. The DNA morphology of the nuclei of each cell was observed at a magnification of 400 times using a fluorescence microscope (Carl Zeiss, Germany). The results are shown in Fig. 3 and Fig.

As shown in FIG. 3 and FIG. 4, the oral cancer cells treated with the extract of Liliaceae according to the present invention had a higher number of cells in which DNA of the nucleus was segmented, depending on the concentration of the extract of Liliaceae extract, compared with oral cancer cells not treated with the extract of Liliaceae Respectively.

Therefore, it can be seen that the extract of Liliaceae of the present invention damages DNA of cells and induces apoptosis in oral cancer cells and exhibits excellent anticancer effect.

2-2. Confirmation of cleaved-caspase-3 and cleaved-PARP expression inhibition of L. berry extract

In order to confirm the mechanism of action of the extract of Liliaceae according to the present invention on the induction of apoptosis of cancer cells, it was found that the important transcription factor cleaved -caspase-3) and cleaved-PARP were measured by Western blot analysis.

Specifically, the human oral cancer cell lines MC1 and HN22 prepared in 1-1 above were divided into 6-well plates, and then cultured to proliferate 50-60% of the cells. MC3 cells cultured in this manner were treated with 2, 4 and 8 占 퐂 / ml of L. berry extract and 5 and 10 占 퐂 / ml of L. bloque extract on HN22 cells, respectively, and cultured for 24 hours. The cells were washed with PBS and lysis buffer was added to recover the cells. The recovered cells were incubated at 4 ° C for 20 minutes and centrifuged at 13,000 rpm at 4 ° C for 15 minutes to obtain supernatant. Protein was quantitated by Bradford assay, and about 30 μg of protein was electrophoresed on SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis). Proteins separated by size by electrophoresis were transferred to a nitrocellulose membrane and fixed with TBST containing 5% skim milk at room temperature for 1 hour and 30 minutes. This was reacted with primary antibody at 4 ° C overnight, washed again with TBST, and reacted with HRP (horse radishperoxidase) -coupled secondary antibody at room temperature for 1 hour and 30 minutes. After the completion of the reaction, the plate was washed with TBST, and the western blotting luminol reagent was applied to the membrane on which the protein was transferred and sensitized using LAS-500. The results are shown in Fig. 5 and Fig.

As shown in FIG. 5, the oral cancer cells treated with the extract of Liliaceae according to the present invention had a cleaved-caspase-3 activity in a concentration dependent on the concentration of the Liliaceae extract, compared with oral cancer cells not treated with the Liliaceae extract of the present invention. 3) expression level was increased.

As shown in FIG. 6, the oral cancer cells treated with the extract of Liliaceae according to the present invention are more effective than cleaved-PARP, which is dependent on the concentration of Liliaceae extract, in comparison with oral cancer cells not treated with the Liliaceae extract of the present invention ) Was increased in the control group.

Thus, the extract of Liliaceae according to the present invention induces apoptosis in oral cancer cells, showing excellent anticancer effect.

2-3. Confirmation of Mcl-1 protein expression inhibition effect of Lily of the Valley

In order to confirm the effect of the extract of the present invention on the factor inhibiting apoptosis of cancer cells, the expression level of Mcl-1 protein was measured by Western blot analysis in the cancer cells treated with the extract of Liliaceae according to the present invention .

Specifically, MC3 cells, the human oral cancer cell lines prepared in 1-1, were dispensed into 6-well plates and cultured to a cell growth of about 50 to 60%. MC3 cells cultured in this manner were treated with 2, 4 and 8 μg / ml of L. radix extracts, cultured for 24 hours, washed with PBS, and lysed by adding lysis buffer. The recovered cells were incubated at 4 ° C for 20 minutes and centrifuged at 13,000 rpm at 4 ° C for 15 minutes to obtain supernatant. Protein was quantitated by Bradford assay, and about 30 μg of protein was electrophoresed on SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis). Proteins separated by size by electrophoresis were transferred to a nitrocellulose membrane and fixed with TBST containing 5% skim milk at room temperature for 1 hour and 30 minutes. The reaction was carried out overnight at 4 ° C with the primary antibody, washed again with TBST, and reacted with HRP (horse radishperoxidase) -seconded antibody at room temperature for 1 hour and 30 minutes. After the completion of the reaction, the plate was washed with TBST, and the western blotting luminol reagent was applied to the membrane on which the protein was transferred and sensitized using LAS-500. The results are shown in Fig.

As shown in FIG. 7, the oral cancer cells treated with the bark extract extract of the present invention showed a decrease in the expression level of Mcl-1 protein depending on the concentration of the extract of Liliaceae extract, compared with oral cancer cells not treated with the extract of the present invention Respectively.

Therefore, it can be seen that the extract of Liliaceae according to the present invention inhibits the Mcl-1 gene which delays the progress of apoptosis in oral cancer cells, thereby promoting the apoptosis of oral cancer cells and exhibiting excellent anticancer effect.

2-4. Effect of Lily of the Valley's Extract on Cytochrome c Concentration in the Cell Substrate

Cytochrome c is a regulator of apoptosis, released into the cell matrix in the mitochondrial inner membrane in response to apoptosis induction stimuli, and activates caspase 9 and cascade activates caspases 3 and 7 to induce apoptosis. In order to confirm the apoptosis-inducing effect of the extract of Liliaceae according to the present invention, the concentration of cytochrome c in the cell matrix in the cancer cells treated with the Liliaceae extract of the present invention was measured.

Specifically, MC3 cells, which are the human oral cancer cells prepared in 1-1, were cultured on a 60 mm plate, and then treated with 0, 2, 4 and 8 / / ml of the extract of Liliaceae according to the present invention. And suspended in a plasma membrane extraction buffer. Then, 0.05% digitonin was added thereto, followed by reaction at room temperature for 1 minute and then centrifuging at 13,000 rpm at 4 ° C for 5 minutes to obtain supernatant (cell matrix fraction). Protein was quantitated by Bradford assay, and about 30 μg of protein was electrophoresed on SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis). Proteins separated by size by electrophoresis were transferred to a nitrocellulose membrane and fixed with TBST containing 5% skim milk at room temperature for 1 hour and 30 minutes. This was reacted with primary antibody at 4 ° C overnight, washed again with TBST, and reacted with HRP (horse radishperoxidase) -coupled secondary antibody at room temperature for 1 hour and 30 minutes. After the completion of the reaction, the plate was washed with TBST, and the western blotting luminol reagent was applied to the membrane on which the protein was transferred and sensitized using LAS-500. The results are shown in Fig.

As shown in FIG. 8, the oral cancer cells treated with the extract of the present invention showed a higher concentration of cytochrome c in the cell matrix than the oral cancer cells not treated with the extract of Liliaceae according to the present invention, Respectively.

Thus, the extract of Liliaceae according to the present invention induces apoptosis in oral cancer cells, showing excellent anticancer effect.

Experimental Example 3. Confirmation of tumor suppression effect of the extract of Liliaceae of the present invention

In order to confirm the tumor suppression effect of the extract of Liliaceae according to the present invention, the degree of phosphorylation of eIF4E and 4EBP1 in the cancer cells treated with the Liliaceae extract of the present invention was measured by Western blot analysis.

Specifically, MC3 cells, the human oral cancer cell lines prepared in 1-1, were dispensed into 6-well plates and cultured to a cell growth of about 50 to 60%. MC3 cells cultured in this manner were treated with 2, 4 and 8 μg / ml of L. radix extracts, cultured for 24 hours, washed with PBS, and lysed by adding lysis buffer. The recovered cells were incubated at 4 ° C for 20 minutes and centrifuged at 13,000 rpm at 4 ° C for 15 minutes to obtain supernatant. Protein was quantitated by Bradford assay, and about 30 μg of protein was electrophoresed on SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis). Proteins separated by size by electrophoresis were transferred to a nitrocellulose membrane and fixed with TBST containing 5% skim milk at room temperature for 1 hour and 30 minutes. This was reacted with primary antibody at 4 ° C overnight, washed again with TBST, and reacted with HRP (horse radishperoxidase) -coupled secondary antibody at room temperature for 1 hour and 30 minutes. After the completion of the reaction, the plate was washed with TBST, and the western blotting luminol reagent was applied to the membrane on which the protein was transferred and sensitized using LAS-500. The results are shown in Fig.

As shown in FIG. 9, the cells treated with the bivalve extract of the present invention showed a decrease in the degree of phosphorylation of eIF4E and 4EBP1 in a concentration-dependent manner, compared with oral cancer cells not treated with the bivalve extract of the present invention.

Therefore, the extract of Liliaceae according to the present invention shows a tumor suppressive effect in oral cancer cells, and thus it is effective in the treatment of cancer.

Hereinafter, a pharmaceutical composition for preventing or treating cancer comprising the extract of Liliaceae according to the present invention as an active ingredient and a preparation example of a food composition for preventing or ameliorating cancer will be described, but the present invention is not limited thereto It is.

Formulation Example 1. Preparation of pharmaceutical preparations

1. Manufacturing of powder

Liliaceae extract 20 mg

Lactose 100 mg

Talc 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

2. Preparation of tablets

Lily of the valley extract 10 mg

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

3. Preparation of capsules

Lily of the valley extract 10 mg

Crystalline cellulose 3 mg

Lactose 14.8 mg

Magnesium stearate 0.2 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

4. Preparation of injections

Lily of the valley extract 10 mg

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na ₂ HPO ₄ .2H ₂ O 26 mg

(2 ml) per 1 ampoule in accordance with the usual injection preparation method.

5. Manufacture of liquids

Liliaceae extract 20 mg

10 g per isomer

5 g mannitol

Purified water quantity

Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.

Formulation Example 2. Preparation of food preparation

1. Manufacture of health food

Lily of the valley extract 100 mg

Vitamin mixture quantity

70 g of vitamin A acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

0.15 mg of vitamin B2

Vitamin B6 0.5 mg

0.2 g of vitamin B12

Vitamin C 10 mg

Biotin 10 g

Nicotinic acid amide 1.7 mg

Folate 50 g

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

2. Manufacture of health drinks

Lily of the valley extract 100 mg

Vitamin C 15 g

Vitamin E (powder) 100 g

19.75 g of ferrous lactate

3.5 g of zinc oxide

Nicotinic acid amide 3.5 g

Vitamin A 0.2 g

Vitamin B1 0.25 g

Vitamin B2 0.3g

Water quantification

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The resulting solution was filtered and sterilized in a sterilized 2 L container, ≪ / RTI >

Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

Claims (6)

A pharmaceutical composition for preventing or treating oral cancer comprising an extract of Liliaceae alcohol as an active ingredient.
The pharmaceutical composition for preventing or treating oral cancer according to claim 1, wherein the alcohol is a C1-C4 alkyl alcohol.
The pharmaceutical composition for preventing or treating oral cancer according to claim 1, wherein the Liliaceae extract is a methanol extract of Liliaceae.
delete The oral cavity of claim 1, wherein the oral cancer is a cancer of the oral squamous cell carcinoma, adenocytic cystic carcinoma, mucinous epidermoid carcinoma, salivary gland carcinoma, sarcoma of the jaw, sarcoma of the facial muscles, malignant melanoma of the oral mucosa, Wherein the cancer is selected from the group consisting of lymphoma, lymphoma, and lymphoma.
A food composition for prevention or improvement of oral cancer comprising an extract of Liliaceae alcohol as an active ingredient.

Images